10/28/2026 – Rakovina Therapeutics and Celvion Therapeutics Complete AI Analysis Identifying Priority Cancer Indications for Brain-Penetrant ATR Inhibitor Program

10/22/2026 – Rakovina Therapeutics and Variational AI Advance Brain-Penetrant ATR Program Toward Development Candidate Selection

10/14/2026 – Rakovina Therapeutics Secures Exclusivity on Optimized kt-5000 Lead Profile from Variational AI

10/1/2026 – Rakovina Therapeutics Partners with Boston-based Celvion Therapeutics to Leverage AI and Real-World Clinical Data for Precision Cancer Drug Development

8/31/2026 – Rakovina Therapeutics Announces Q2 2026 Financial Results and Provides Corporate Update

8/31/2026 – Rakovina Therapeutics Announces Final Closing of Upsized Non-Brokered Private Placement

8/19/2026 – Rakovina Therapeutics Announces Results from 2026 Annual General Meeting

8/12/2026 – Rakovina Therapeutics Announces Closing of First Tranche, Upsize and Extension of Non-Brokered Private Placement